Is the focus of the RFA primarily on cutting edge therapies? Can methodological issues be studied?
The purpose of this Request for Applications (RFA) is to establish a Heart Failure Clinical Research Network that will accelerate research in the diagnosis and management of heart failure, in order to improve outcomes through optimal application of existing therapies and evaluation of novel therapies. As stated in the RFA, the network will focus on collaborative clinical protocols to facilitate application of emerging basic science discoveries into clinical investigations. For example, proposed protocols may evaluate cell-based treatments, treatments using novel classes of drugs such as immunomodulators, or genetic or other new biomarkers for early diagnosis and assessment of therapy. Since this RFA focuses on translation of new basic science findings, protocols focused on behavioral and lifestyle interventions, large Phase III clinical trials, or epidemiologic studies are not responsive to this solicitation.
The purpose of this Request for Applications (RFA) is to establish a Heart Failure Clinical Research Network that will accelerate research in the diagnosis and management of heart failure, in order to improve outcomes through optimal application of existing therapies and evaluation of novel therapies. As stated in the RFA, the network will focus on collaborative clinical protocols to facilitate application of emerging basic science discoveries into clinical investigations. For example, proposed protocols may evaluate cell-based treatments, treatments using novel classes of drugs such as immunomodulators, or genetic or other new biomarkers for early diagnosis and assessment of therapy. Since this RFA focuses on translation of new basic science findings, protocols focused on behavioral and lifestyle interventions, large Phase III clinical trials, or epidemiological studies are not responsive to this solicitation.
